A new gene is found to be a factor of judgment for Alzheimer's disease

Alzheimer's disease researchers at the US University of Wisconsin found a group of biomarkers, which can help to identify which older people are more likely to suffer from Alzheimer's disease before showing the symptom of dementia. The study was published in the journal Brain, which also published some studies on recombinant human proteins.

"The Association of Alzheimer's Disease estimates that if we have the precautionary approach five years before the appearance of clinical symptoms, then half of the patients who develop dementia would survive from the disease," lead author of the study Annie Racine said. "In other words, we can save millions of lives and save billions of dollars."

Doctor Sterling Johnson who is senior author of the study said, "Changes in the brain - such as the emergence β- amyloid plaques and interlacing with tau proteins - are biomarker of Alzheimer's disease. Not every who have such changes in brain will show Alzheimer's disease. The study found that biomarkers can predict who will develop the disease.

The study included 175 elderly people who have the risk of Alzheimer's disease. According to brain scans and pathologic features of these participants, researchers divided the participants into four groups. The researchers conducted 10 years of follow-up to the participants to monitor changes in cognitive abilities of participants in different groups.

The results showed that the performance of the biomarkers of one group of participants acted well and had a good prediction role on Alzheimer's. In the group of 22 participants, in the group of 22 participants, APOE4 gene of two-thirds of participants were positive, this biomarker is the biggest risk factor for sporadic Alzheimer's disease.

Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. We provide recombinant proteins such as recombinant CDH11 at competitive prices.